OKAZAKI Hiroshi
Ph.D.
After completing my Master's degree in Pharmaceutical Sciences, I joined the Kirin Brewery in 1984. I have experienced the process of biopharmaceutical companies being born, growing, and becoming independent from beer companies. Targets and modalities are important factors in drug discovery, but I have been particularly surprised to see modalities to open up new industries. Program Director of DMP since April 2021.
FUJII Shin-ichiro
M.D., Ph.D.
After gaining clinical experience as a hematologist, including hematopoietic stem cell transplantation, I have been studying immunology with the aim of discovering drugs that control immunity. To translate scientific evidence obtained from basic research into drug discovery, it is necessary to conduct preclinical studies not only on drug efficacy but also on safety and pharmacokinetics and to evaluate the results from a clinical perspective. We will provide support for the translation of basic research into clinical practice.
KOIZUMI Tomonobu
Ph.D.
Using the cross-appointment system, I led and promoted drug discovery research from the dual standpoints of a pharmaceutical company and a university. In addition, I served as an advisor in AMED/JST projects. By leveraging these industry–academia–government collaborations for drug discovery, I will contribute to the social implementation of excellent academic outcomes.
HONMA Teruki
Ph.D.
I have been involved in drug design in 14 years at pharma and 15 years at RIKEN. Recently, I was assigned as the principal investigator in AMED Next-Generation Drug Discovery AI Project (DAIIA). We aim to develop design methods that integrate molecular simulations and AI, in particular, FMODB, the world's first quantum chemical calculation database for proteins, were released.
MORINAGA Chikako
Ph.D.
Leveraging experience in academia-driven regenerative medicine clinical research project management and at the PMDA Office of Cellular and Tissue-based Products, Morinaga supports translational research focused on cell therapy and regenerative medicine development.
MATSUOKA Nobuya
Ph.D.
I have been a scientific leader in pharmaceuticals with extensive experience in strategic line management and cross-functional project management, with a track record of delivering high-quality compounds for clinical studies. I hope to work together with RIKEN scientists on state-of-the-art medical innovations to translate them into novel therapeutics. Join us in our drug discovery initiative aiming to make life better for people around the world!
OHGAMI Kinya
Ph.D.
I would like to support and promote concepts and projects originated from basic research seeds and ideas in the academia to realize innovative medicine by leveraging the knowledge and experience obtained through my various careers, such as drug discovery research, research planning, open innovation, and business development in the pharmaceutical industry.
OZAKI Ken-ichi
Ph.D.
I led drug discovery research in the research division of a pharmaceutical company and worked in their business division to promote personalized healthcare and maximize the value of development projects based on competitive intelligence. With a belief in “Right Target - Right Drug - Right Patient,” I am driven to contribute to the integration of scientific innovation into society.
FUJITA Shigeo
Ph.D.
During my time at a pharmaceutical company, I was involved in upstream small-molecule drug discovery research, which included single-crystal structural analysis, protein structure analysis, NMR spectroscopy, MS spectroscopy, molecular design, combinatorial synthesis, HTS, sample management, data management, natural product drug discovery, and so on. I also support cutting-edge computational research in AI and MD and try to build external partnerships.
YAMAGUCHI Tokio
Ph.D.
During my time at a pharmaceutical company, I was involved in upstream small-molecule drug discovery research, which included single-crystal structural analysis, protein structure analysis, NMR spectroscopy, MS spectroscopy, molecular design, combinatorial synthesis, HTS, sample management, data management, natural product drug discovery, and so on. I also support cutting-edge computational research in AI and MD and try to build external partnerships.
YAMASHITA Makoto
Ph.D.
Applying my experience in the discovery and launching of antivirals at a Japanese pharmaceutical
company and in basic research at Tokyo University, I will support all efforts on infectious
diseases at DMP.
Visiting Professor, Aichi Medical University
TOMIZUKA Kazuma
Ph.D.
Leveraging experience in drug discovery and R&D in biopharmaceutical company, Tomizuka
transitioned to an academic setting in 2018 to conduct research and teaching in the area of
biotechnology. He supports your research activities from the perspective of creating new value
and business from science.
Professor, Laboratory of Bioengineering, Department of Applied
Life Sciences, Faculty of Life Sciences, Tokyo University of Pharmacy and Life Sciences
MACHIYA Koji
Ph.D.
I was engaged in process research from initial development to technology transfer to factories at a pharmaceutical company as well as global application and domestic regulatory affairs issues. Utilizing these experiences and knowledge, I will support manufacturing under GMP control that ensures consistent quality and the establishment of CMC strategies.
TAKEUCHI Rie
As a secretary to Program Director, I work on various tasks at DMP, such as arranging meetings and paperwork. I always aim at creating a better environment for members to work comfortably toward DMP’s goals.
KISE Haruko
I am responsible for managing conferences, compiling program results, and performing other supporting duties. I will do my best to ensure that the program proceeds smoothly.
YASUDA Mayuko
I am in charge of conducting searches for drug discovery, prior art, competitors, patents, markets, compounds, and data analysis. My major is in Organic Chemistry.
MAEDA Kaori
Ph.D., MBA
During my over 20 years of experience in project management and business development with a global pharmaceutical company in Japan, I have successfully completed several transactions. At DMP, I coordinate the preparation of alliance strategies and support negotiations with possible partners. I support business negotiations for research institutes at the Japan Agency for Medical Research and Development.
FUTAMI Takashi
Ph.D., MBA
I look forward to supporting DMP drawing on my experiences as a researcher, strategist, capitalist, and entrepreneur/founder in a pharmaceutical company, a start-up venture, and the venture capital field.
UEMURA Naoto
M.D., Ph.D.
A physician specializing in clinical pharmacology, Uemura was for many years involved in
research and development of groundbreaking drugs at a leading pharmaceutical company. He now
applies the knowledge and experience he gained there to pursue the academia-driven development
of new therapies and their translation to clinical applications from a global
perspective.
Head of Oita University Hospital’s Clinical Pharmacology Center.
TAKAYAMA Takuya
M.D., Ph.D.
As a surgeon, I not only administer multidisciplinary treatments such as cancer surgery and chemotherapy, but also have experience conducting physician-initiated phase-1 clinical trials of immunotherapy for cancer at core cancer hospitals. I will support how to implement new treatments developed at RIKEN in clinical practice.
SUZUKI Hiromi
B.Pharm, MBA
I planned and managed clinical development and NDA operations and responded to PMDA reviews in a global pharmaceutical company. Several products have been approved by MHLW. Moreover, I conducted clinical studies as part of a global clinical development team. I continue to support the clinical development of projects based on my experience.
KAWAMURA Akio
Ph.D.
Leveraging pharma company experience in preformulation design, physical property evaluation,
drug discovery and development stage pharmacokinetic research, as well as rich experience in
approval of applications including document-based conformity inspection, Kawamura supports drug
discovery and medical technology theme and project research and development.
Director of Drug
Metabolism and Pharmacokinetics, and Drug Delivery, Central Research Laboratories, Senju
Pharmaceutical Co., Ltd.
MIYAMAE Yoichi
Ph.D.
Miyamae leverages many years of experience in drug development, particularly in non-clinical
toxicity evaluation, to support the translation of Program for Drug Discovery and Medical
Technology Platforms themes and projects to the private sector and medical
institutions.
Director, Shin Nippon Biomedical Laboratories, Ltd., and former General Manager
of Scientific Affairs, Preclinical Services Company
MATSUYAMA Kotone
B.Pharm,GFMD, IFAPP
Matsuyama handles development planning and regulatory affairs management. She specializes in
project management and clinical pharmacology, and has experienced data management, medical
writing, project management, and coordination of industry-university collaboration in Academic
Research Organization (ARO) since the dawn of ARO in Japan.
Specially Appointed Professor of
Department of Health Policy and Management, Nippon Medical School and Deputy Director of the
Center for Strategic Research Initiative, Nippon Medical School Foundation.
The business development office handles alliances for collaboration with companies, universities, and external research institutes. It is also involved in licensing intellectual property rights to companies in collaboration with RIKEN Innovation.
Mission of Translational Research Office (TRO), the competent team which consists of number of experts of translational research (TR) from industry, academic TR institutes, regulatory organizations, is to support projects establishing clinical development plan.
